The primary benefit of pediatric exclusivity is the increased availability of pediatric-specific medications. By incentivizing pharmaceutical companies to conduct pediatric studies, it ensures that more drugs are tested and approved for use in children, leading to safer and more effective treatments. Additionally, pediatric exclusivity can lead to the identification of new uses for existing drugs, optimizing therapeutic options for young patients.
